Compugen Ltd. announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | +1.05% | +1.05% | -3.03% |
Mar. 08 | Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating | MT |
Mar. 05 | Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.03% | 172M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CGEN Stock
- News Compugen Ltd.
- Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer